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Abstract NSCLC cells with a mesenchymal phenotype
have shown a marked reduction in sensitivity to EGFR
inhibitors, though the molecular rationale has remained
obscure. Here we find that in mesenchymal-like tumor cells
both tyrosine phosphorylation of EGFR, ErbB2, and ErbB3
signaling networks and expression of EGFR family ligands
were decreased. While chronic activation of EGFR can
promote an EMT-like transition, once having occurred
EGFR family signaling was attenuated. We investigated
the mechanisms by which mesenchymal-like cells bypass
EGFR signaling and acquire alternative routes of prolifer-
ative and survival signaling. Mesenchymal-like NSCLC
cells exhibit aberrant PDGFR and FGFR expression and
autocrine signaling through these receptors can activate the
MEK-ERK and PI3K pathways. Selective pharmacological
inhibition of PDGFR or FGFR receptor tyrosine kinases
reduced cell proliferation in mesenchymal-like but not
epithelial NSCLC cell lines. A metastable, reversible
EMT-like transition in the NSCLC line H358 was achieved
by exogenous TGFb, which served as a model EMT sys-
tem. The H358/TGFb cells showed many of the attributes
of established mesenchymal-like NSCLC cells including a
loss of cell-cell junctions, a loss of EGF-family ligand
expression, a loss of ErbB3 expression, increased EGFR-
independent Mek-Erk pathway activation and reduced
sensitivity to EGFR inhibition. Notably an EMT-dependent
acquisition of PDGFR, FGFR and TGFb receptors in
H358/TGFbeta cells was also observed. In H358/TGFbeta
cells both PDGFR and FGFR showed functional ligand
stimulation of their intrinsic tyrosine kinase activities. The
findings of kinase switching and acquired PDGFR and
FGFR signaling suggest investigation of new inhibitor
combinations to target NSCLC metastases.
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Introduction
As human cancers progress to a more invasive, metastatic
state, altered cell signaling is required to prevent apoptotic
and anoikis signals associated with epithelial cell detach-
ment [1]. Recent data highlight the transdifferentiation of
epithelial cancer cells to a more mesenchymal-like state, a
process resembling epithelial-mesenchymal transition
(EMT) [2, 3], to facilitate cell invasion and metastasis [4, 5].
Through EMT-like transitions mesenchymal-like tumor
cells are thought to gain migratory capacity at the expense of
proliferative potential. A reverse mesenchymal-epithelial
transition (MET) has been postulated to regenerate a more
proliferative state and allow macrometastases resembling
the primary tumor to form at distant sites [6]. The transition
of tumor cells at the stromal-tumor interface to a more
mesenchymal-like state likely plays a role in the progression
of cancer [7, 8] and has been correlated with poor prognosis
[9, 10]. Our previous studies have shown that the cellular
changes associated with EMT-like transitions alter the
dependence of carcinoma cells on epidermal growth factor
receptor (EGFR) signaling networks for proliferation and
survival. An EMT-like transition has been associated with
NSCLC tumor cell, xenograft and patient insensitivity to
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selective EGFR tyrosine kinase inhibition [11–13], in part
from EGFR independent activation of either or both the
PI30kinase or Mek-Erk pathways [14]. Similar data corre-
lating EMT status to sensitivity to EGFR TKIs have been
reported in pancreatic, CRC [14] bladder [15] and HNSCC
[16] cell lines, xenografts and in patients samples [13]. The
molecular determinants to alternative routes of activation of
the PI30kinase and/or Erk pathways, which can bypass cel-
lular sensitivity to EGF receptor inhibitors, have been
actively investigated. For example within an epithelial tumor
context IGF-1R activation has been associated with insen-
sitivity to EGFR inhibition [17, 18], likely through
compensatory IGF-1R-PI3K-Akt signaling rendering EGFR
family signaling redundant. Similarly the amplification of
the HGF receptor tyrosine kinase, c-Met, has been shown to
compensate for EGFR inhibition in part through recruitment
of ErbB3 to activate the PI30kinase—Akt pathway [19].
However the mechanism by which mesenchymal-like tumor
cells attenuate their dependence on EGFR signaling and
survive as single cells lacking cell–cell junctions has not
been actively investigated.
The principle aim of this study was to identify alterna-
tive redundant signaling pathways utilized by
mesenchymal-like NSCLC lines which might contribute to
cell proliferation and survival independently of EGFR.
Two models were studied: one where the NSCLC line
H358 was induced to undergo an EMT-like transition by
exogenous TGFbeta, the other where NSCLC lines with
epithelial and mesenchymal phenotypes were compared
and contrasted at the molecular level. Mesenchymal
NSCLC lines showed attenuation of cell–cell junction and
cell-polarity constituents, and increased expression of
alternative autocrine signaling which might render EGFR
redundant. In H1703 cells autocrine PDGFR and FGFR
pathways contributed to activation of PI30K-Akt and Mek-
Erk pathways, and conversely cell proliferation could be
attenuated by PDGFR and FGFR inhibitors. These data
implicate EMT as a mechanism for kinase switching,
thereby decreasing cellular sensitivity to EGFR inhibition.
Materials and methods
Cell culture and growth inhibition assay
The human NSCLC lines (H292, H358, H322, H441, A549,
Calu6, H460, H1703, SW1573, H266, H522, H650, Calu1 and
H23) were cultured in the appropriate ATCC recommended
supplemented media. The molecular characteristics of these
NSCLC cell lines are detailed at http://www.sanger.ac.uk/
genetics/CGP/cosmic/. For growth inhibition measurements
cells were plated and allowed to proliferate for 24 h. Serial
dilutions of the indicated drug were added and the cells grown
for a further 72 h. Cell viability was determined by chemilu-
minescent measurement of cellular ATP concentration
(CellTiterGlo, Promega; #G7572). The inhibitors used were
erlotinib (TarcevaTM, OSI Pharmaceuticals/Genentech/
Roche), OSI-930 (OSI Pharmaceuticals), PD173074 (Sigma-
Aldrich, #P2499), CP-673451 (Pfizer).
Immunoblot analysis of NSCLC cell line extracts
Cell lines were treated as indicated in the figure legends.
Cell lysates were prepared in RIPA buffer (Sigma,
#R0278) containing protease (Sigma #P8340) and phos-
phatase (Sigma, #P5726) inhibitors. Protein concentration
was determined by micro-BCA assay (Pierce, #23227).
Protein immunodetection was performed by electrophoretic
transfer of SDS-PAGE separated proteins to nitrocellulose,
incubation with antibody and chemiluminescent second
step detection (PicoWest; Pierce, #34078). The antibodies
used were : E-cadherin (sc21791), N-cadherin (#7939),
ErbB3 (sc285), pPDGFR (Tyr 754, #12911), pPDGFR
(Tyr720, #12910), GAPDH (#25778) and Zeb1 (#25388),
all from Santa Cruz Biotechnology; vimentin (BD550513)
and fibronectin (BD610077; both from BD Biosciences);
EGFR (#2232), pEGFR (pTyr1068, #2234), PDGFRa
(#3164), PDGFRb (#3961), FGFR1 (#3472), pErk (#9101),
Erk (#9102), pAkt(ser473, #9271), Akt (#9272), all from
Cell Signaling Technologies), b-actin (Sigma, #A5441).
RNA isolation and RT-PCR analysis
Total RNA was isolated from cell lines (Qiagen, #74104).
First strand cDNA was synthesized and RT-PCR per-
formed (Perkin Elmer, N808-0236) on an Applied
Biosystems 7300 real-time PCR instrument.
TGFb treatment of NSCLC cells
Recombinant TGFb3 was added to the cell culture media to
a final concentration of 1 nM and was replenished every 2–
3 days. Cell extracts were isolated and analysed as
described above. Inhibition of cell proliferation was mea-
sured after 48 h drug treatment by BrdU incorporation and
immunodetection (Roche; #11647229001). Apoptosis
induction was monitored after 48 h drug treatment by
caspase 3/7 activation using the CaspaseGlo reagents
(Promega, #G8092).
Preparation of cell extracts and anti-phosphotyrosine
affinity capture
Cytosol [F1], membrane [F2] and nuclear [F3]-enriched
fractions were prepared using ProteoExtract reagent
([20]; EMD Bioscience, #444810). Afterwards, proteins
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were precipitated using trichloroacetic acid/deoxycholate
coprecipitation, resuspended in 8 M urea, reduced with
5 mM tributylphosphine (Sigma-Aldrich, #T7567; 1 h at
RT), alkylated with iodoacetamide (15 mM for 1.5 h at
RT), diluted to 1 M urea and subject to proteolysis with
20 lg trypsin (Sigma-Aldrich, #T6567; 37C, 18 h). Pep-
tides were acidified with trifluoroacetic acid (TFA) and
desalted using C18 resin. Cell surface capture was per-
formed by biotinylation, solubilization of the membrane
lipids and recovery of the crosslinked proteins on strepta-
vidin solid-phase resin (Pierce, #89881). Samples were
adjusted to 8 M urea, reduced, alkylated and proteolyti-
cally cleaved with trypsin as described above.
Anti-phosphotyrosine immunoaffinity selection was per-
formed essentially as previously described [21]. Proteins
isolated by anti-phosphotyrosine affinity chromatography
were reduced, alkylated, cleaved with trypsin and labeled
with iTRAQ stable isotope tags as previously described [22,
23] using a different isobaric tag to label peptides from dis-
tinct NSCLC cell lines (H292, H358, Calu6, H1703, A549,
H460 and H1650) or different time points following EGFR
inhibition with erlotinib. After labeling, the peptides were
further fractionated by cation exchange chromatography
followed by offline C18 desalting.
Protein identification and quantitation by liquid
chromatography-electrospray ionization tandem mass
spectrometry
Peptide masses, peptide sequence information and peptide
quantitation were obtained by liquid chromatogra-
phyelectrospray ionization tandem mass spectrometry
(LC-MS/MS) and protein database searching. Information-
dependent MS and MS-MS acquisitions were made on a
Qq-TOF instrument (Applied Biosystems/MDS Sciex) as
previously described [22]. Data were collected using
Analyst QS (Version 1.1; Applied Biosystems/MDS
Sciex). Proteins were identified at [95% confidence from
survey and product ion spectra data, searching human
sequences within the UniProt protein database (releases
from 10/05 to 01/07) using the Paragon algorithm of Pro-
teinPilot (Version 2.0; Builds 44649beta and 50861;
Applied Biosystems/MDS Sciex). When multiple isoforms
were detected, only peptides specific to each detected form
were used, which factored in ion counts for weighting in
the protein ratio calculation [24]. Protein identification
complied with the guidelines of [25] where 2 or more
unique isoform-specific peptides were required for inclu-
sion. Parsimony of protein results was assured by rigorous
protein inference with the ProGroup algorithm. Proteins
identified with C95% confidence with relative abundances
between cell states in the upper and lower distribution
quartiles ([75% or \25%) with a t-test P value (for any
difference between cell line or biological condition) of
\0.05 were further considered.
Results
Attenuated EGFR, ErbB2 and ErbB3 signaling
in NSCLC lines with a mesenchymal phenotype
Previously we and others have reported that sensitivity of
tumor cell lines, carrying wild type EGFR, to EGFR
tyrosine kinase inhibitors is correlated with an epithelial to
mesenchymal transition of the cells and not with total
EGFR abundance or K-Ras mutational status [11–13].
Here, in a large panel of NSCLC lines the mesenchymal
phenotype correlated with insensitivity to the selective
EGFR inhibitor erlotinib (Fig. 1a), consistent with our
previous findings [11]. Implicit in these observations is the
suggestion that cells which have undergone an EMT have
acquired EGFR-independent mechanisms of cell survival
and proliferation. In order to better understand the signal-
ing mechanisms by which mesenchymal-like cells bypass
EGFR signaling we compared protein and phosphoprotein
expression changes in a panel of NSCLC lines with epi-
thelial and mesenchymal-like phenotypes by quantitative
tandem mass spectrometry [22]. Validating this approach,
tandem mass spectrometry experiments showed an atten-
uation of cell polarity and cell junction signaling
complexes in cells with a mesenchymal-like cell phenotype
(Table 1). We observed reductions in EGFR autophos-
phorylation at C-terminal sites Y1148 and Y1068 and
ErbB2 tyrosine phosphorylation in mesenchymal-like cells
compared to epithelial cells.
Next we measured RNA transcript abundance encoding
ligands for the EGFR family (TGFa, epiregulin, amphi-
regulin, neuregulin-1, neuregulin-2 and betacellulin). The
downregulation of EGFR signaling in the mesenchymal
cells correlated with a decrease in autocrine EGF ligand
production (Fig. 1b) and decreased EGFR, ErbB2 and
ErbB3 phosphorylation and total ErbB3 protein [11, 26].
We asked whether EGFR could be activated by exogenous
ligand in mesenchymal like lines. EGF stimulation of
EGFR autophosphorylation at Y1068 was observed in all
NSCLC lines examined, irrespective of epithelial or mes-
enchymal phenotype (Fig. 1c). Similarly, EGF stimulation
of downstream substrate phosphorylation, for example Erk,
Akt (Fig. 1c), Shc and Cbl (data not shown) could be
inhibited by addition of the EGFR inhibitor erlotinib in
cells with both epithelial and mesenchymal phenotypes. It
is important to note that the basal (non-EGF stimulated)
levels of phospho-Erk and phospho-Akt could only be
inhibited with erlotinib in the epithelial and not the mes-
enchymal-like cells (Fig. 1c).
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Acquisition of PDGFR and FGFR signaling
in mesenchymal NSCLC
We explored the hypothesis that the relative insensitivity of
mesenchymal-like NSCLC lines to EGFR TKIs was med-
iated by the acquisition of alternative proliferative and
survival networks. We therefore undertook an analysis of
potential pathways that may be bypassing EGFR signaling
in these cells. All of the NSCLC lines expressed PDGF
ligands, irrespective of whether their phenotype was mes-
enchymal-like or epithelial. In contrast, none of the four
epithelial cell lines expressed either PDGFRa or PDGFRb,
whereas 8/13 of the mesenchymal-like lines expressed one
or other of the receptors (Fig. 2a). The expression of the
PDGF receptors was further confirmed by immunoblot of
NSCLC cell extracts (Fig. 2b). This was of interest as
PDGF receptors are normally restricted to cells of meso-
dermal origin [27]. Interestingly, the mesenchymal NSCLC
line H1703 showed markedly increased levels of transcripts
encoding PDGFRa and PDGF-B ligand (Fig. 2a) relative to
the epithelial lines. H1703 cells also exhibited highly ele-
vated tyrosine phosphorylation of PDGFRa and of
downstream substrates for example PI30kinase-p85, STAT3
and SHP-2 (Table 1), whose phosphorylation were reduced
in epithelial NSCLC lines. To test active PDGFR coupling
to the PI30kinase pathway, the p85 subunit of PI30kinase
was immunoprecipitated from H1703 cells and co-precip-
itating proteins identified by LC-MS/MS. Both p85a, p85b
and p110a subunits of PI30kinase were detected and the
only receptor tyrosine kinase recovered was PDGFRa.
To evaluate the consequences of PDGFR inhibition on
the proliferation of mesenchymal-like NSCLC lines, two
TKIs were employed to discriminate off target effects. A
thiophene Kit/Kdr/Flt1/PDGFR inhibitor (OSI-930) [28]
and a chemically distinct, more selective, quinolinyl
PDGFR inhibitor (CP673451) [29] were used. From four
mesenchymal-like cell lines (H1703, Calu1, Calu6 and
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Fig. 1 An EMT in NSCLC cell lines correlates with a reduction in
autocrine EGFR signaling. (a) An epithelial marker profile correlates
with erlotinib sensitivity in NSCLC cell lines. The indicated cell lines
were immunoblotted with antibodies against epithelial markers (E-
cadherin and ErbB3) and mesenchymal markers (Zeb1 and vimentin).
GAPDH was used as a loading control. (b) Erlotinib insensitive
mesenchymal-like cell lines exhibit decreased expression of EGF
ligands. Total RNA was prepared form each of the indicated cell lines
and the expression levels of the indicated EGF family ligands were
determined by RT-PCR. (c) Basal EGFR signaling is inhibited in
epithelial cell lines but not mesenchymal-like cell lines. The indicated
cell lines were treated with erlotinib for 2 h and then left untreated
(Con) or stimulated with EGF (25 ng/ml, 15 min). Cell lysates were
then probed with the indicated antibodies. Beta-actin was used as a
loading control
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was only observed in H1703 cells (Fig. 3a). OSI-930
inhibited both basal and PDGF-stimulated PDGFRa, Erk
and Akt activation in H1703 cells but not in the epithelial
control line H292 lacking PDGFR (Fig. 3b). H1703
response to PDGFR inhibition may derive from relatively
high expression of PDGF-BB ligand and the creation of a
strong autocrine signaling loop. H226 and Calu1, shown to
express PDGFRb but little PDGF-B chain, did not show
autocrine PDGFR activation and were not growth inhibited
by either of the two distinct PDGFR inhibitors.
Table 1 Proteins and phosphoproteins differentially expressed between mesenchymal (Calu6, H1703) and epithelial (H292, H358) cell states





Cell fraction Mesenchymal:Epithelial protein ratios (Dlog2)
Calu6:H292 H1703:H292 Calu6:H358 H1703:H358
Receptor tyrosine kinase tyrosine phosphorylation decreased in mesenchymal-like NSCLC cells
P00533 EGFR pY-1148 – 5 – -2.14* -1.41 -1.42 -0.69
EGFR pY-1086 – 7 – -0.72 -0.95 -1.05 -1.28
P04626 pY-ErbB2 43 185 pY-B -1.01** -0.62** -1.49** -1.11**
20 83 pY-S -0.43** -0.33* -1.38** -1.32**
P07949 pY-Ret 10 13 pY-B 2.24* nd 1.26 nd
9 27 pY-S 1.65** nd 2.07** nd
PDGFR auto and substrate phosphorylation increased in mesenchymal-like H1703 cells
P16234 pY-PDGF-Ra 13 22 pY-B 1.44** 1.58**
P42338 pY-P13K p100b 6 8 pY-B 1.17 1.52**
P27986 pY-P13K p85a 7 22 pY-B 1.57 1.90
Q06124 pY-SHP2 24 61 pY-B 0.83** 1.20**
P40763 STAT3 1 5 F2 1.08** 1.82**
4 4 pY-B 1.85 1.57
4 18 F1 1.19** 1.84**
Representative lineage-specific markers altered in mesenchymal-like NSCLC cells
P31947 14-3-3s (Stratifin) 12 86 F1 -2.26** -2.69** -1.87** -2.25**
4 19 F2 -1.63** -2.24** -1.16** -1.74**
5 6 pY-B -0.40 -2.37 -0.35 -1.04
P12830 E-Cadherin 1 1 F2 -2.30 -1.99 -2.44 -2.04
20 64 pY-B -1.35** -1.44** -0.99** -0.94**
P22223 P-Cadherin 4 6 pY-B -2.14* -1.63 -1.45* -0.97
P35221 a-Catenin 10 60 F2 -1.50** -1.42** -1.39** -1.58**
94 518 pY-B -1.56** -1.68** -1.03** -1.23**
22 66 pY-S -0.85** -0.77** -0.90** -0.87**
P35222 b-Catenin 10 41 F2 -0.91** -1.89** -0.90** -1.94**
25 92 pY-B -1.22** -0.98** -0.67* -0.43
9 15 pY-S -0.59** -0.65** -0.51* -0.63**
O60716 d-Catenin 9 27 F2 -0.76** -0.84** -0.74** -0.84**
105 765 pY-B -1.50** -1.81** -0.90** -1.24
28 191 pY-S -0.99** -1.25** -1.47** -1.69**
P08670 Vimentin 18 75 F2 0.94* 1.12** 1.50** 1.56**
103 908 pY-B 2.74** 2.59** 2.77** 2.66**
41 466 pY-S 2.08** 2.10** 2.30** 2.25**
Proteins significantly decreased in either mesenchymal-like lines Calu6 or H1703, are expressed as log2 ratios relative to both epithelial cell
backgrounds (denominators H292 and H358). At least two biological experiments were performed (N1 and N2) each of which was analyzed in
multiple ion exchange fractions in 2–3 LC-MS/MS experiments per fractions, expressed as log2. Proteins and phosphoproteins identified from
two biological experiments with a 95% confidence interval were quantitated and mesenchymal to epithelial ratios determined (Dlog2) together
with its statistical significance (* \0.05; ** \0.01). The number of isoform-specific unique peptides and total peptides used for quantitation
(sample size) are indicated. Cell fractions included cytoplasmic-enriched (soluble; F1) and membrane-enriched (particulate; F2). Phosphoprotein
fractions included steady-state (pY-B) or serum-stimulated (pY-S) conditions. nd; not detected (i.e. cell specific)
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We next examined whether interaction between PDGFR
and EGFR signaling pathways could be observed. The
H1703 line expressed relatively high levels of both PDGFR
and EGFR, and showed increased PDGFR autophospho-
rylation and substrate-phosphorylation when EGFR was
inhibited by erlotinib. EGFR blockade significantly
increased phosphorylation of multiple PDGFR substrates,
notably PDGFRa itself, PI30kinase p85 and p110 subunits,
SHP-2, COOL-2 and PLCc (Fig. 3c). The EGFR TKI
mediated increase in PDGFR autophosphorylation was
confirmed by immunoblot using anti-phosphoPDGFR
antibodies to Y754 and Y720 (Fig. 3d).
We determined the relative abundance of RNA tran-
scripts encoding receptor tyrosine kinases and signaling
pathways which might activate Akt and/or Erk in an
EGFR-independent manner. RT-PCR measurements of
FGFR levels indicated FGFR1 was the predominant iso-
form expressed in mesenchymal-like NSCLC cell lines
(Fig. 4a). Immunoblot of NSCLC line lysates with anti-
FGFR antibodies confirmed FGFR1 was expressed pre-
dominately in the mesenchymal-like cell lines (data not
shown). Three mesenchymal-like NSCLC cell lines H1703,
Calu1 and H226, showing elevated expression of FGFR1, 3
and 4 were treated with increasing concentrations of a
specific inhibitor of FGFR1 and FGFR3 (PD173074,
Sigma) and cell proliferation measured (Fig. 4b). H1703
and H226 cells were growth inhibited by treatment with
PD173074, with little effect observed in Calu1 cells. FGFR
inhibition had an effect primarily upon Erk signaling and to
a lesser extent on Akt signaling in H1703 and H226 cells
whereas no effect was observed in the epithelial control
line H292 (Fig. 4c). H226 mesenchymal-like cells showed
increased FGFR abundance and were growth inhibited by
FGFR blockade, while H1703 utilized both FGFR and
PDGFR pathways to activate the PI30kinase and Ras
pathways and stimulate cell proliferation.
Cell signaling changes in H358 cells undergoing
an EMT-like transition
We next asked whether the changes in signaling axes used
in mesenchymal-like cells compared to epithelial cells
could be initiated by an EMT-like transition. To this end
we developed an isogenic in vitro EMT model wherein
activation of the TGFb pathway induced a fibroblastic
transition in vitro [2, 30]. Exposure of H358 cells to TGFb
(1 nM) over 14 days resulted in a marked reduction in E-
cadherin and ErbB3, coupled to an increased expression of
the mesenchymal markers vimentin and Zeb1 (Fig. 5a), a
scattered cellular phenotype and increased motility (data
not shown). These phenotypic changes could be prevented
by co-treatment with the TGFb receptor inhibitor
SB431542 (data not shown) and reversed by removal of
TGFb from the culture media (Fig. 5a). Consistent with
reports that TGFb-inducible EMT in vitro is a rare event
[30], a complete transition was observed only in H358
cells. A partial EMT phenotype could be achieved in H322
and A549 cells after 14 days (data not shown).
We next examined the effects of EMT on cellular sen-
sitivity to EGFR inhibition. H358/TGFb cells were less
sensitive to the growth inhibitory effects of erlotinib than
parental H358 cells, showing an approximate 7 fold shift in
half-maximal effective concentration (Fig. 5b). In addition,
H358/TGFb cells were approximately 1.5 fold less sensi-
tive to erlotinib-induced apoptosis (Fig. 5b). EGFR TKI
treatment of H358 cells resulted in inhibition of the basal
phosphorylation of Erk (Fig. 5c). In contrast H358/TGFb
cells exhibited elevated steady-state activation of Erk (as
measured by phosphorylation T202/Y204) which could only
partially be inhibited by EGFR blockade (Fig. 5c). In
control experiments where TGFb-induced EMT was
blocked by co-treatment with the TGFb receptor inhibitor
SB431542, Erk phosphorylation was inhibited by EGFR
blockade in a similar fashion to the parental control H358
cells (data not shown).
To determine whether the EMT induced changes in the
H358/TGFbeta model were reflective of those observed in
established mesenchymal-like NSCLC we measured the
expression of EMT marker genes by RT-PCR (Fig. 6a).












































































































Fig. 2 Acquisition of PDGFR signaling in mesenchymal-like
NSCLC lines. (a) NSCLC cell lines express PDGF receptors and
their cognate ligands. Total RNA was prepared from the indicated cell
lines and the expression level of PDGF receptors and PDGFs were
measured by RT-PCR. (b) Expression of PDGF receptors in
mesenchymal-like NSCLC cell lines. Protein extracts from the
indicated cell lines were analysed by immunoblot with the indicated
antibodies
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factors implicated in the EMT process, such as Snail, Zeb1
and Zeb2 [31]. H358/TGFb cells expressed reduced levels
of EGF family ligands, in particular TGFa, epiregulin and
amphiregulin (Fig. 6a), consistent with the observed down
regulation of EGF ligands in the committed mesenchymal-
like NSCLC cells (Fig. 1b). In addition, again consistent
with the committed mesenchymal-like cells, we observed
an up regulation of the RNA transcripts encoding
PDGFRa, PDGFRb, PDGF-A and FGFR1 in the H358/
TGFb cells relative to their parental counterpart (Fig. 6a).
To determine whether these receptors were functional in
the transitioned cells we stimulated H358 cells, which had
been induced to undergo EMT (Fig. 6b), with either
PDGF-AA/BB or acidic FGF/basic FGF ligand mixtures.
Extracts were immunoprecipitated with an anti-phospho-
tyrosine antibody and then probed for the presence of either
PDGFR or FGFR1 (Fig. 6c). Both PDGFR and FGFR1
were shown to be activated and functional in response to
ligand only in cells in which an EMT-like transition was
observed.
Discussion
Tumor-derived cells, likely located at the tumor-stromal
interface, can transition to a more migratory invasive state
through activation of specific biological pathways resem-
bling an epithelial-to-mesenchymal-like transition [6]. This
transition can allow the cells to escape the site of primary
tumor formation, resist anokis and seed in distant sites prior
to development of a metastatic lesion. The similarity of
stroma and adjacent tumor has been reported in colon
carcinoma [32]. This phenotypic behavior is associated
with extensive genetic reprogramming, most notable
through the actions of a family of transcription factors such
as Snail, Zeb [31], FOXC2, HMGA and Twist. These
factors play critical roles in mesoderm formation during
embryonic development and can protect cells from apop-
tosis in vitro [33, 34]. The sensitivity of tumor cells to the
EGFR tyrosine kinase inhibitor erlotinib has been reported
to correlate with EMT status in multiple cancer lines.
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Fig. 3 Autocrine PDGFR signaling regulates cell proliferation in
mesenchymal-like NSCLC line H1703. (a) Inhibition of PDGFR
signaling in H1703 cells inhibits cell proliferation. Cells were plated
in 96 well dishes and treated with increasing concentrations of OSI-
930. Cell proliferation was measured after 72 h. Data from 3
independent experiments (mean ± SEM) is plotted as percentage of
the untreated control. (b) Inhibition of PDGFRa, Erk and Akt
signaling by a PDGFR antagonist in the mesenchymal-like NSCLC
cell line H1703 vs. the epithelial control line H292. The indicated cell
lines were treated with drug (OSI-930, 0, 1 or 10 lM, 2 h) and then
left untreated or treated with PDGF (10 ng/ml, 10 min). Cell lysates
were prepared and protein extracts analysed by western blot with the
indicated antibodies. (c) Inhibition of EGFR signaling in H1703 cells
increases PDGFR signaling. H1703 cells were either untreated or
treated with erlotinib (10 lM, 2 h) then stimulated with EGF (10 ng/
ml, 10 min) and phospho-proteins captured using an anti-phospho-
tyrosine antibody. The recovered proteins were analysed by LC-MS/
MS and changes in PDGFR signaling associated proteins expressed as
log2 changes between treated and control samples (* P \ 0.05;
** P \ 0.01). (d) H1703 cells were treated with the indicated
concentrations of erlotinib (2 h) and then left untreated (Con) or
stimulated with EGF (10 ng/ml, 10 min). Cell extracts were analysed
by western blotting with the indicated antibodies
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able to predict sensitivity to the actions of the drug, but did
not provide a mechanistic explanation as to the reason why
mesenchymal-like cells were less sensitive.
We have undertaken a molecular analysis of the mes-
enchymal-like and epithelial NSCLC cell lines to establish
a mechanistic basis for the differential sensitivity. Phos-
pho-proteomic measurements of the cell lines gave an
indication that EGFR signaling was attenuated in the
mesenchymal-like lines, through the decreased levels of
pEGFR and pErbB2 peptides recovered, and this was
linked to the decreased levels of EGF ligand expression in
these cell lines. This observation, coupled with the
decrease in ErbB3 levels in the mesenchymal lines, gives a
strong rationale for the observed decreased erlotinib sen-
sitivity. These data suggested a significant down-regulation
of the EGFR, ErbB2 and ErbB3 signaling network in cells
which have undergone an EMT compared to their epithelial
counterparts. Importantly we have also demonstrated that
this shift in flux through the EGFR pathway is a direct
result of the EMT, as treatment of H358 cells with TGFb
results in all the hallmarks of EMT, including reduced
EGFR inhibitor sensitivity, and a down regulation of EGF
ligand production and ErbB3 protein levels. Together these
data suggest that epithelial tumor cells have a strong
dependency upon autocrine EGF signaling for cell survival
and proliferation and that as they undergo an EMT this
dependency is lost due to a down regulation of autocrine
EGF ligand production and a down regulation of ErbB3
protein levels. Paradoxically chronic activation of EGFR
signaling can promote EMT-like transitions [35, 36], but
once having occurred, these pathways are no longer acti-
vated and mesenchymal tumor cells acquire alternative
survival signals.
These data led us to set the hypothesis that the mesen-
chymal-like erlotinib insensitive cell lines had acquired
alternative modes of signaling for survival and prolifera-
tion. In NSCLC lines we correlated EMT to the acquisition
of autocrine PDGFR and FGFR signaling, further defining
the mechanism for insensitivity of mesenchymal-like
NSCLC cell lines to EGFR blockade. All these cell lines
were derived from EGFR TKI-therapy naive patients and
so have acquired these alternative signaling mechanisms as
a consequence of tumor progression and EMT. The aber-
rant expression of PDGFRs in epithelial-derived carcinoma
cells is less well studied. In stable mesenchymal NSCLC
lines with autocrine PDGFR or FGFR activation (eg.
H1703 and H226), onco-addiction to these receptor tyro-
sine kinases could be observed. We show a strong
dependence on PDGFR signaling in H1703 cells, where
PDGFR inhibition led to decreased activation of PI3K-Akt
and Mek-Erk pathways and reduced proliferation. Recently
Rikova et al. [37] reported similar observations to that
presented here and in addition showed that H1703 xeno-
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Fig. 4 Acquisition of FGF signaling in mesenchymal-like NSCLC
cell lines.; (a) NSCLC cell lines express FGF receptor-1. Total RNA
was prepared from the indicated cell lines and the expression level of
FGF receptors were determined by RT-PCR. (b) Inhibition of FGF
signaling in mesenchymal-like NSCLC cell lines inhibits cell
proliferation. Cells were plated in 96 well dishes and treated with
increasing concentrations of PD173074. Cell proliferation was
measured after 72 h. Data from 3 independent experiments
(mean ± SEM) was plotted as a percentage of the untreated control.
(c) Inhibition of Erk and Akt signaling by an FGFR antagonist in
mesenchymal-like NSCLC cell lines. The indicated cell lines were
treated with drug (PD173074; 0, 1 or 10 lM, 2 h) and then left
untreated or treated with basic FGF (50 ng/ml, 10 min). Cell lysates
were prepared and protein extracts analysed by western blot with the
indicated antibodies
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imatinib, further supporting a role for PDGFR in this
NSCLC cell line. The majority of the mesenchymal-like
NSCLC lines expressed PDGFRb, however these lines did
not express PDGF ligands, and so PDGFRb was not
autophosphorylated and cells were not inhibited by PDGFR
receptor inhibitors. However functional PDGF receptor on
these mesenchymal-like cell lines could potentially be
activated by paracrine PDGF within an in vivo tumor
microenvironment, not mimicked in vitro. Of note is that
the metastable cells induced to undergo EMT by TGFb
treatment did not show a dependency upon autocrine
PDGFR signaling (data not shown), but were clearly able
to respond to ligand stimulation, suggesting a potential
paracrine role for PDGFR signaling in the mesenchymal-
like state in vivo. The expression of PDGFRs in mesen-
chymal-like NSCLC lines is consistent with increased
PDGF signaling in mouse mammary cells induced to
undergo EMT [38], where it was observed to be of critical
importance in maintaining the mesenchymal-like state.
Further, expression of both forms of PDGFR has been
reported in late stage human mammary carcinomas [39]
implying a role in more advanced aggressive disease, a
scenario in which EMT is particularly relevant [6].
The acquisition of FGFR expression is equally inter-
esting, as again this receptor has primarily been studied in
the context of its role in angiogenesis. The presence of
FGFR1 in mesenchymal-like cells coupled to its increased
gene expression during TGFb-induced EMT strongly
implicates it in a role in mesenchymal-like cell function,
and here we have shown two NSCLC cell lines (H1703 and
H226) which utilize autocrine FGFR signaling for prolif-
eration. In addition cells that are induced to undergo an
EMT exhibit acquisition of functional FGFR1 suggesting a
potential role for paracrine FGFR signaling in mesenchy-
mal—like cells. FGF2 has been reported to stimulate an
EMT in vitro [40] and tumor cells exhibiting autocrine
FGFR signaling were mesenchymal in nature [41] consis-
tent with the results presented here. Similarly an interaction
between FGFR1 and the mesenchymal marker N-cadherin
has been reported to be important in regulating ERK sig-
naling, MMP9 expression and the invasive phenotype of




























































Fig. 5 TGFb induces EMT in H358 cells and reduces erlotinib
sensitivity. (a) TGFb-induces a reversible EMT in H358 cells. H358
cells (Con) were treated with TGFb3 (+TGFb) and then TGFb3
removed from the culture media (+TGFb/-TGFb). Protein extracts
were analysed by western blotting with the indicated antibodies. A
representation of the transition from epithelial to mesenchymal and
back to epithelial phenotypes is shown below. (b) TGFb-induced
EMT results in reduced sensitivity to erlotinib-mediated growth
inhibition and apoptosis. H358 cells were treated with TGFb (1 nM,
21 days) plated in 96 well dishes and treated with increasing
concentrations of erlotinib. Cell proliferation was measured 48 h
after erlotinib treatment by analyzing BrdU incorporation and data
from 2 independent experiments is plotted as a percentage of the
untreated control. Apoptosis was measured 48 hours after erlotinib
treatment by caspase 3/7 activation. Data from 2 independent
experiments is plotted as fold induction over the untreated control.
(c) TGFb-induced EMT results in increased basal Erk1/2 activity and
reduced erlotinib inhibition of Erk1/2 kinase activity. H358 cells were
treated with TGFb as in (a). The cells were then treated with
increasing concentrations of erlotinib for 2 h. Protein extracts were
analysed by western blot with the indicated antibodies
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Crosstalk between EGFR and PDGFR pathways was
observed in the mesenchymal cell line H1703. Inhibition of
EGF stimulated EGFR signaling by erlotinib in H1703
cells induced phosphorylation and activation of PDGFR
and downstream signaling. Cross-talk between EGFR and
Met RTKs [43] and between EGFR and IFG1R RTKs [44]
has been previously reported. This further reinforces the
notion of EGFR TKI therapy being of limited effectiveness
against that fraction of tumor cells which have undergone
an EMT-like transition. Whether the increased PDGFR
signaling relates to EGFR-mediated saturation of internal-
ization, as has been suggested in v-src transformation [45],
remains to be determined.
Our observations contrasting H358 and H358/TGFb
isogenic lines as a model of metastable EMT-like transition
in vitro further recapitulated many of the findings with
established stable NSCLC lines. However, one important
difference was the reversibility of the process, in this case
by removal of TGFb from the culture medium. Although
the TGFb-induced EMT can be blocked by inhibition of
TGFb signaling with a small molecule inhibitor, the
established mesenchymal-like NSCLC cell lines could not
be induced to revert to an epithelial cell phenotype even
upon prolonged TGFb receptor inhibition (data not shown).
Interestingly initial data also suggest that when TGFb
induced mesenchymal-like cells revert back to an epithelial
state, EGFR activation and EGFR TKI sensitivity are not
immediately restored suggesting some memory of signal-
ing changes associated with the EMT transition persist in
the absence of mesenchymal markers (data not shown). It
was been proposed that upon arrival at a secondary site,
mesenchymal cells can revert to an epithelial state and
reinitiate a proliferative signaling program [6]. The TGFb-
induced EMT model may therefore be a better reflection of
the metastable EMT process, whereby continued exoge-
nous TGFb, or by analogy paracrine signaling, is required
to maintain the mesenchymal-like state. These data also
suggest that the established mesenchymal-like NSCLC
lines have become epigenetically arrested in the mesen-
chymal state, potentially analogous to spindle cell



































































































































Fig. 6 Metastable mesenchymal-like H358/TGFb cells initiate func-
tional PDGFR and FGFR expression. (a) Gene expression changes
upon TGFb-induced EMT in H358 cells. H358 cells were treated with
TGFb for 7 days and total RNA was isolated from the cells.
Expression of the indicated genes was analysed by RT-PCR and the
fold change in expression in TGFb-treated cells compared to control
cells determined. Data from 2 independent experiments is plotted as
log2 fold change on the Y axis, with positive values indicating an
increase and negative values indicating a decrease in gene expression
in the TGFb-treated cells. (b) H358 cells were treated with TGFb
(1 nM) for 1 week or 4 weeks and protein extracts analyzed for the
expression of E-cadherin and vimentin. (c) TGFb-induced EMT of
H358 cells induces the expression of functional PDGFR and FGFR
receptors. H358 cells treated with TGFb for 1 or 4 weeks were treated
with PDGF-AA/BB (10 ng/ml, 10 min) or acidic FGF/basic FGF
(10 ng/ml, 10 min) and extracts immunoprecipitated with an anti-
phosphotyrosine antibody (PY-100). Immunoprecipitated proteins
were analyzed for the presence of PDGFRa/b or FGFR1 by
immunoblot
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We suggest a model where tumor cells can utilize
multiple mechanisms to bypass EGFR dependence. In an
epithelial state EGFR TKI resistance mechanisms include
IGF1R activation, Met amplification and EGFR T790M
mutation. In cells with a more mesenchymal state EGFR
TKI resistance can be correlated with autocrine PDGFR
and FGFR signaling. Recent data suggest patients with
metastasis can have heterogeneous tumors that can contain
epithelioid cells within the tumor and mesenchymal-like
derived from an EMT-like transition cells at the tumor-
stroma interface [46]. Specific targeted therapies directed
against mesenchymal-like cell survival pathways would be
predicted to reduce tumor metastasis and progression.
Therefore, the observation that tumors can acquire PDGFR
and FGFR autocrine signals through an EMT-like transi-
tion, suggest new therapeutic modalities to target both
epithelial and mesenchymal tumor phenotypes that may
support cancer progression and recurrence [47].
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